Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared a post on X:
“GU schedule by day for ASCO26 and (among others), looking forward to.
- Bladder CA:
- Data on novel nectin-4 ADCs: NEXUS01, EXCEED plus DURAVELO2, Bulumtatug, SHR-A2102
- Updates for: EV302, KN905 QoL
- RAD-IO TMT w/ durva
- GemFLP in bladder adenoCA.
- Kidney CA:
- NonCC-RCC: cadonilimab (PD1/CTLA4 bispecific),final ph2 cabo/nivo
- Updates: KN564 ctDNA
- Panitumumab-based EGFR block in SAMRCB1-deficient RMC
- Prostate CA:
- PROTEUS: perioperative apalutamide (plenary!)
- mCSPC: identifying docetaxel benefit analyses from CHAARTED plus ENZAMET, and ADT interruption ADREAM, PARPi TALAPRO3, PSMAddition, ZZ-First
- mCRPC: ADC to PSMA/STEAP1, PLUDO doce vs Lu-617, AVPC chemo-IO.
- Testicular CA:
- SWOG S1823 microRNA in predicting active GCT
- Expert session on Optimizing Tx for Pts with Poor-Risk Testicular Cancer.”
Other articles featuring Karine Tawagi on OncoDaily.
